Thailand’s Advanced Therapy Medicinal Products (ATMP) and cell banking sector is witnessing a key milestone, as Medeze Group Public Company Limited (SET: MEDEZE) elevates its operational standards to align with global best practices.
Dr. Veerapol Khemarangsan, CEO of MEDEZE, stated that these advancements are setting the stage for Thailand to become Asia’s hub for advanced medical therapies, as the nation focuses on building trust in treatment safety and quality.
Central to this effort is the implementation of rigorous “Cell Bank Standards,” with stem cells serving as the core raw material for pharmaceuticals and advanced therapies. Dr. Veerapol emphasized that the quality of these stem cells directly impacts the reliability and international acceptance of final medical products.
MEDEZE has recently cleared two stringent evaluations by Thailand’s Department of Medical Sciences in January and May, both grounded in ISO and international guidelines. These audits addressed every aspect of quality, safety, and full traceability in the cell storage process.
The company has also established comprehensive quality control measures, guaranteeing traceability from the origin of cells through to their processing and storage. Other core systems include environmental management, radiation shielding, and fire prevention—further fostering trust among clients, hospitals, as well as both domestic and international partners.
As Thailand’s society ages and life expectancy rises, MEDEZE is supporting the country’s research acceleration in advanced procedures. This includes cartilage cell-based osteoarthritis therapies, regenerative treatments for skin and hair, CAR-T and NK cell cancer therapies, and research into non-communicable diseases like diabetes, kidney disease, and Alzheimer’s. Upgraded standards for egg and embryo banking are also underway to advance reproductive and preventive medicine.
Collaboration with Chulalongkorn University, a GMP-certified institution, further strengthens MEDEZE’s clinical research capabilities as the company works to upgrade its facilities to meet GMP certification by the end of this year—a move critical for commercializing innovative ATMP products.
International expansion is key to MEDEZE’s growth strategy. The company aims to become Asia’s leading cellular banking provider, with immediate efforts focused on entering the Philippine market and achieving market leadership within a year. Plans are also advancing for a new cell banking center in Mongolia, with future expansions targeting Indonesia, United Arab Emirates (UAE), Russia, and Vietnam.
Dr. Veerapol highlighted that the global ATMP market exceeds $60 billion and grows by 14-15% annually, presenting strong long-term prospects. Thailand’s strength in medical expertise, infrastructure, and cost competitiveness is set to enhance its regional standing.
Attaining international certification is expected to increase MEDEZE’s Thai market share from 60% to up to 80% as competitors work to align with these standards.
Supporting policy initiatives, particularly Sandboxes policy for new treatment trials, and increased research funding are helping the sector stay competitive globally and attract foreign investment to Thailand’s health economy.
MEDEZE focuses on a business-to-business (B2B) model, developing advanced medical products in partnership with hospitals and clinics, rather than establishing its own institutions. This strategy seeks to strengthen the ecosystem, reduce competition for medical talent, and establish Thailand as a hub of medical innovation in the region.
